Tag: omisirge market growth

  • What’s Driving Growth in the Omisirge Market? Insights into Key Trends and Opportunities

    What’s Driving Growth in the Omisirge Market? Insights into Key Trends and Opportunities

    Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

    How has the omisirge market grown in recent years?

    The market size of omisirge has witnessed an XX (HCAGR) growth in the past few years. Forecasts predict a rise from $XX million in 2024 to $XX million in 2025, representing an annual compound growth rate (CAGR) of XX%. This growth during the historical period can be linked to the increased cases of chronic diseases, the surge in clinical trials, the growing elderly population, the improvement in healthcare infrastructure, and an upswing in research and development activities.

    How is the omisirge market size expected to evolve during the forecast period?

    The size of the omisirge market is projected to register an FCAGR of XX% in the upcoming years. By 2029, the market value is anticipated to reach $XX million through the compound annual growth rate (CAGR) of XX%. The growth during the forecasted period can be linked to heightened healthcare spending, increased government initiatives, a rise in disposable income, a surge in personalized medicine, and higher rates of cancer incidences. Key trends within this period will involve an emphasis on new product launches, tactical partnerships, technological advancements, drug authorizations from regulatory bodies, and investment in research and development activities.

    Get your omisirge market report here!

    https://www.thebusinessresearchcompany.com/report/omisirge-global-market-report

    Which key drivers are propelling the omisirge market’s growth?

    The omisirge market is expected to expand due to the increased incidence of cancer. Cancer, a range of diseases typified by uncontrolled growth and spread of abnormal cells, can invade nearby tissues and organs, possibly leading to fatal complications when unaddressed. Rising cancer rates can be credited to a combination of factors such as increased exposure to carcinogens like tobacco smoke, UV radiation, and several chemicals, an ageing population, changes in diet and lifestyle, and certain genetic alterations. Omisirge is an innovative treatment that aids cancer patients by targeting and adjusting the immune system to boost the body’s inherent cancer-fighting capabilities, providing a hopeful therapeutic route for some forms of cancer, particularly those that defy conventional therapies. As per the American Cancer Society, a non-profit cancer advocacy organization based in the US, the count of cancer cases surged to 1,958,310 in 2023, reflecting a 3.16% increase from 1,898,160 in 2021. Consequently, the escalating prevalence of cancer is fueling the growth of the omisirge market.

    What are the market segments in the omisirge industry?

    The omisirge market covered in this report is segmented –

    1) By Clinical Indication: Leukemia; Lymphoma; Myeloma; Other Hematologic Malignancies

    2) By Distribution Channel: Direct Sales; Distributors

    3) By End User: Hospitals And Clinics; Ambulatory Surgical Centers

    Get your free sample now – explore exclusive market insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20269&type=smp

    Which leading companies are shaping the growth of the omisirge market?

    Major companies operating in the omisirge market are Gamida Cell Ltd.

    What key trends are currently impacting the omisirge market’s development?

    A significant trend in the omisirge market entails acquiring drug approval from regulatory bodies in order to enhance competitiveness in the sector. This approval process involves a rigorous review and permission granted by regulatory bodies for a new drug’s sale, premised on its safety, effectiveness, and quality, as proven by clinical trials data. Take, for example, Gamida Cell Ltd., an American biotech firm that in April 2023 received approval from the U.S. Food and Drug Administration to sell Omisirge for both adult and pediatric patients aged 12 and above suffering from hematologic malignancies who have undergone umbilical cord blood transplantation following myeloablative conditioning. This milestone signifies a huge leap forward in cell therapy for patients with blood cancer since omisirge aids in speeding up neutrophil recovery and lessening infection risk. Omisirge, given as a single intravenous dose, comprises human allogeneic stem cells cultivated with nicotinamide, a variant of vitamin B3. Instead of utilizing the patient’s own cells, a healthy stem cell from an unrelated but meticulously chosen donor is used to create each patient’s dose.

    Unlock exclusive market insights – purchase your research report now for a swift delivery!

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20269

    Which geographic areas are influencing the growth of the omisirge market?

    North America was the largest region in the omisirge market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omisirge market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Browse Through More Similar Reports By The Business Research Company:

    Blood Cancer Drugs Global Market Report 2025

    https://thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

    Global Autologous Cell Therapy Global Market Report 2025

    https://thebusinessresearchcompany.com/report/autologous-cell-therapy-global-market-report

    Stem Cell Therapy Global Market Report 2025

    https://thebusinessresearchcompany.com/report/stem-cells-therapy-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Omisirge Market Forecast and Analysis: Key Insights into Growth, Trends, and Emerging Opportunities

    Omisirge Market Forecast and Analysis: Key Insights into Growth, Trends, and Emerging Opportunities

    Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

    How Will the Growth Rate of the Omisirge Market Shape Industry Trends by 2034?

    The scale of the omisirge market has escalated by XX (HCAGR) in the past few years. Projected growth is expected to take it from a valuation of $XX million in 2024 to $XX million in 2025, marking a compound annual growth rate (CAGR) of XX%. Factors such as the growing incidence of chronic diseases, escalation in clinical trials, an ageing population, expanding healthcare infrastructure, along with a surge in research and development activities have been key drivers of growth during the historical period.

    In the coming years, the omisirge market size is predicted to witness XX (FCAGR). By 2029, it is projected to reach a valuation of $XX million, growing at a compound annual growth rate (CAGR) of XX%. The escalation during the forecast period can be ascribed to factors like increased spending on healthcare, enhanced government policies, upsurge in disposable income, a rise in tailored medicines, and heightened prevalence of cancer. Noteworthy trends throughout the prediction period encompass product inauguration, strategic partnerships, technological progressions, drug authorization by governing bodies, and commitments towards research and development.

    What Major Innovations Are Driving the Accelerated Growth of the Omisirge Market?

    The increase in cancer cases is anticipated to fuel the omisirge market’s growth. Cancer comprises a set of diseases epitomized by the unchecked expansion and spread of anomalous cells, which may infiltrate nearby organs and tissues, possibly metastasizing to diverse parts of the body. If not treated, this can lead to lethal complications. The upsurge in cancer cases owes to a mix of factors. These include escalating exposure to carcinogens like tobacco smoke, UV radiation, and certain chemicals, augmented by the aging population, modifications in dietary and lifestyle habits, and specific genetic mutations. Omisirge serves as a state-of-the-art treatment, benefitting cancer patients by aiming at and adjusting the immune system to amplify the body’s inherent cancer-fighting capabilities. This offers an optimistic therapeutic strategy for certain cancer types, especially those immune to conventional treatments. For example, as stated by the American Cancer Society, a non-profit cancer advocacy entity based in the US, the cancer cases ascended to 1,958,310 in 2023, showing a 3.16% increase from 1,898,160 in 2021. Thus, the escalating frequency of cancer is triggering the omisirge market’s expansion.

    Get Your Free Sample of the Global Omisirge Market Report Now!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20269&type=smp

    Who Are the Key Market Players Influencing the Growth of the Omisirge Industry?

    Major companies operating in the omisirge market are Gamida Cell Ltd.

    What Key Market Trends Are Shaping the Future of the Omisirge Industry?

    One key development in the omisirge market is the attainment of drug authorization from regulating bodies to secure a competitive advantage in the sector. Drug authorization encompasses the assessment and approval of a new drug for usage and sale by regulatory bodies, ensuring its safety, efficacy, and quality based on data from clinical trials. For instance, in April 2023, the U.S. Food and Drug Administration gave its approval to Gamida Cell Ltd., a biotechnology company based in the US, for the usage of Omisirge in adult and pediatric patients aged 12 and above suffering from hematologic malignancies who undergo umbilical cord blood transplantation after myeloablative conditioning. This approval signals a significant step forward in cell therapy for patients with blood cancer, as Omisirge is engineered to speed up neutrophil recovery and decrease the risk of infection. Administered in a single intravenous dose, Omisirge is made up of human allogeneic stem cells grown with nicotinamide (a type of vitamin B3). Each dose for the patients is prepared using healthy stem cells from a carefully picked unrelated donor, instead of the patient’s own cells.

    Get Instant Access to the Global Omisirge Market Report with Swift Delivery!

    https://www.thebusinessresearchcompany.com/report/omisirge-global-market-report

    What Are the Main Segments of the Omisirge Market, and How Are They Evolving?

    The omisirge market covered in this report is segmented –

    1) By Clinical Indication: Leukemia; Lymphoma; Myeloma; Other Hematologic Malignancies

    2) By Distribution Channel: Direct Sales; Distributors

    3) By End User: Hospitals And Clinics; Ambulatory Surgical Centers

    Which Regions Are Emerging as Leaders in the Omisirge Market?

    North America was the largest region in the omisirge market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omisirge market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    What Are the Defining Features of the Omisirge Market?

    Omisirge is an advanced cell therapy used in allogeneic hematopoietic stem cell transplantation (HSCT) for patients with blood cancers or disorders. It is derived from umbilical cord blood and designed to expedite neutrophil recovery, reducing the risk of infection and complications after transplantation. Omisirge contains expanded hematopoietic progenitor cells (CD34+ cells) cultured to enhance their number and functionality, enabling faster engraftment compared to standard cord blood transplantation.

    Browse Through More Similar Reports By The Business Research Company:

    Blood Cancer Drugs Global Market Report 2025

    https://thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

    Global Autologous Cell Therapy Global Market Report 2025

    https://thebusinessresearchcompany.com/report/autologous-cell-therapy-global-market-report

    Stem Cell Therapy Global Market Report 2025

    https://thebusinessresearchcompany.com/report/stem-cells-therapy-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on: